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Abstract
IL-10 is a Th2 cytokine important for inhibiting cell-mediated
immunity while promoting humoral responses. Human IL-10
(hIL-10) has anti-inflammatory, immunosuppressive as well as
immunostimulatory characteristics, whereas viral IL-10 (vIL-10),
a homologue of hIL-10 encoded by Epstein Barr virus (EBV),
lacks several immunostimulatory functions. The
immunostimulatory characteristic of hIL-10 has been attributed
to a single amino acid, isoleucine at position 87, which in vIL-10
is alanine. A mutant hIL-10 in which isoleucine has been
substituted (mut.hIL-10) is biologically active with only
immunosuppressive, but not immunostimulatory, functions,
making it a potentially superior therapeutic for inflammatory
diseases. To compare the efficacy of mut.hIL-10 with hIL-10 and
vIL-10 in blocking the progression of rheumatoid arthritis, we
used replication defective adenoviral vectors to deliver intra-
articularly the gene encoding hIL-10, vIL-10 or mut.hIL-10 to
antigen-induced arthritic (AIA) knee joints in rabbits. Intra-
articular expression of hIL-10, vIL-10, and mut.hIL-10 resulted in
significant improvement of the pathology in the treated joints to
similar levels. These observed changes included a significant
reduction in intra-articular leukocytosis and the degree of
synovitis, as well as normalization of cartilage matrix metabolism.
Our results suggest that hIL-10, vIL-10, and mut.hIL-10 are all
equally therapeutic in the rabbit AIA model for treating disease
pathology.
Introduction
Rheumatoid arthritis (RA) is a debilitating, autoimmune disor-
der characterized by chronic erosive inflammation of the joints
with invasive proliferation of synovial cells into the articular car-
tilage and attendant bone destruction. Pro-inflammatory
cytokines, particularly tumor necrosis factor (TNF)-α, and IL-1
are thought to be important mediators that drive the patho-
physiology of RA [1-4]. Considerable progress has been
reported with the use of biological agents that mediate the
pathogenesis of RA, including interleukin-1 receptor antago-
nist (IL-1Ra), antibodies to IL-1 and TNF-α, and soluble TNF-α
receptors [5-10]. In particular, sTNF-R (Enbrel), anti-TNF anti-
body (Remicade), and IL-1Ra (Kinaret) are commercially avail-
able. Unfortunately, these protein-based biological agents
have a short half-life, requiring weekly subcutaneous or intra-
venous delivery. Conversely, intra-articular transfer of the
genes encoding immunomodulatory agents is an effective
approach to achieve high, localized and sustained levels fol-
lowing a single treatment. Several studies in different animal
models of RA clearly show that in vivo gene delivery to one
diseased joint is highly effective in ameliorating disease not
only in that joint, but in the contralateral joints as well [11-13].
One cytokine that has been of interest as a therapeutic for RA
is IL-10. It is a key cytokine found in the human immune
response that inhibits cell-mediated immunity and inflamma-
tion while promoting humoral responses [14]. It is a 35 kDa
non-covalent homodimer produced by macrophages, B-lym-
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phocytes and Th2 cells, and is a potent inhibitor of Th1
cytokines [15]. This activity accounts for its initial designation
as a cytokine synthesis inhibition factor (CSIF) [16].
The actions of IL-10 are diverse in that IL-10 can be anti-
inflammatory, immunosuppressive or immunostimulatory,
depending upon the target cell. However, the principal func-
tion of IL-10 appears to be anti-inflammatory, limiting and even-
tually terminating inflammatory responses by inhibiting
synthesis of monocyte and macrophage derived pro-inflamma-
tory cytokines [15-19]. IL-10 also has the ability to inhibit the
antigen-presenting function of monocytes/macrophages and
dendritic cells through the down-regulation of MHC class II
molecules and the co-stimulatory molecules B7 and intercellu-
lar adhesion molecule-1 (ICAM-1), classifying it as an immuno-
suppressive cytokine [20-24]. In addition to these activities, IL-
10 has some immunostimulatory properties; it regulates
growth and/or differentiation of B cells, natural killer cells, cyto-
toxic and helper T cells, mast cells, granulocytes, dendritic
cells, keratinocytes, and endothelial cells. IL-10 plays a key
role in differentiation and function of the regulatory T cell
[25,26].
Human IL-10 (hIL-10) exhibits 73% homology with murine IL-
10 (mIL-10) and 84% with the open reading frame of the
Epstein-Barr virus (EBV), initially known as BCRF1 or now
termed as viral IL-10 (vIL-10) [27]. vIL-10 shares many of the
anti-inflammatory properties of mIL-10 and hIL-10, but lacks
their immunostimulatory properties [24,25]. Isoleucine at posi-
tion 87 of murine and human IL-10 is crucial for the immunos-
timulatory function. This amino acid in viral IL-10 is alanine.
Studies have shown that by substituting isoleucine with
alanine at position 87 in hIL-10, the immunostimulatory
response could be abrogated, leaving the mutant human IL-10
(mut.hIL-10) biologically active with only immunosuppressive
activity and receptor species specificity [28]. Various studies
of inflammatory situations, in mouse tumor models, cardiac
allograft experiments, and endotoxemic models, have all sug-
gested a potential superiority of vIL-10 over hIL-10 as an
immunosuppressive agent [29-31]. vIL-10 has also been
tested in the antigen induced arthritis (AIA) rabbit model and
the collagen induced arthritis mouse model and shown to con-
fer a significant therapeutic effect [11,12,32,33].
In this study, we used the rabbit AIA model to compare directly
the therapeutic efficacy of hIL-10, vIL-10, and mut.hIL-10,
encoded by genes delivered intra-articularly in vivo by adeno-
viral vector. We demonstrate that expression of hIL-10, vIL-10
or mut.hIL-10 in the rabbit joints were similarly effective not
only in preventing the progression of the disease by blocking
leukocytic infiltration, but also reducing the degree of synovitis,
as well as normalizing cartilage metabolism. These results sug-
gest that the three variants of IL-10, hIL-10, vIL-10, and
mut.hIL-10, are all equally therapeutic when delivered locally in
the rabbit experimental arthritis model.
Materials and methods
Adenovirus vectors
The recombinant vectors used in this study were E1/E3
deleted replication-defective type 5 adenoviruses [34]. The
cDNA encoding either hIL-10, vIL-10, mut.hIL-10 or enhanced
green fluorescent protein (eGFP) was inserted into the E1
region with gene expression driven by the early promoter of the
human cytomegalovirus. High titer recombinant adenoviruses
(Ad.hIL-10, Ad.vIL-10, Ad.mut.hIL-10, and Ad.eGFP) were
generated as described previously [35] by Cre-Lox driven
homologous recombination and permissive replication in
CRE8 cells, a 293 cell-line (ATCC, MD) that expresses Cre
recombinase. Viral titers were determined by optical density at
260 nm (OD260) where 1 OD unit = 1012 viral particles [36].
Rabbits
Female New Zealand White rabbits, weighing approximately 5
to 6 lbs each, were purchased from Myrtles Rabbitry (Thomp-
son Station, TN, USA) and housed in the Central Animal Facil-
ity at the University of Pittsburgh. The animals were
acclimatized for three days before experimentation and were
fed chow ad libitum and water. All animal experiments were
conducted in accordance with NIH standards of animal care
and the animal protocol used for this study was approved by
the animal ethics committee of the University of Pittsburgh.
Experimental protocol
The rabbits were sensitized by a series of two intradermal
injections of 5 mg of chick ovalbumin (OVA; Sigma, St. Louis,
MO, USA), emulsified in Freund's complete adjuvant (Pierce,
Rockford, IL, USA) and Freund's incomplete adjuvant (Pierce)
respectively, given 10 days apart [37]. Acute monoarticular
arthritis was induced in both knee joints two weeks after the
booster shot by intra-articular injection of OVA dissolved in 0.5
ml saline.
Twenty-four hours post-initiation of AIA, 5 × 109 particles of
replication-defective adenovirus encoding either hIL-10, vIL-
10, mut.hIL-10 or eGFP (control) was suspended in 0.2 ml
sterile saline and injected into the joint space via the patellar
tendon.
On days 3 and 7 post adenoviral delivery, the rabbit knee joints
were lavaged by the injection of 1 ml of Gey's balanced salt
solution (Gibco-BRL, Grand Island, NY, USA) into the joint
space via the patellar tendon. After manipulation of the joint,
the needle was reinserted and the fluid aspirated. Leukocytes
suspended in the recovered lavage fluid were counted using a
hemocytometer. Levels of IL-10 in recovered lavage fluids and
sera were measured using a cytokine ELISA kit (Pierce
Endogen, Rockford, IL, USA).
Cartilage metabolism
To quantify the glycosaminoglycans (GAGs) released into the
joint space as a result of cartilage proteoglycan breakdown,Available online http://arthritis-research.com/content/8/4/R91
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the lavage fluid from days 3 and 7 were first centrifuged at
14,000 × g for 10 minutes to get rid of all the debris, and the
supernatant recovered. Aliquots (100 µl) of this supernatant
were treated with papain to enzymatically cleave the proteins.
Then, 20 µl of papain suspension (Type III, 19 U/mg protein;
Sigma) was added to 1 ml of buffer containing 10 mM sodium
EDTA and 0.4 M sodium acetate, pH 5.2. This papain solution
(100 µl) was added to 100 µl of lavage fluid supernatant and
incubated overnight at 60°C. Papain was then inactivated by
iodoacetic acid (Sigma) to a final concentration of 4 mM. The
samples were centrifuged at 14,000 × g for 10 minutes, and
the supernatant transferred to fresh tubes; 2 U of hyaluronate
lysase (Sigma) was added and the samples incubated at 37°C
overnight. Sulfated GAG concentrations were measured as
previously described [38] by a colorimetric dye binding assay
using 1,9-dimethylmethylene blue reagent.
To measure the rate of proteoglycan synthesis, the harvested
knees were dissected, and fragments of articular cartilage
were shaved from the femoral condyles. Cartilage fragments
weighing approximately 30 to 40 mg were incubated in 1 ml
Newman and Tyell serum-free media (Gibco-BRL) with 40 µCi
35SO4
2- for 24 hours at 37°C. At the end of this incubation, the
media was recovered and stored at -20°C. The cartilage frag-
ments were subsequently incubated in 1 ml 0.5 M NaOH at
4°C with gentle agitation for 24 hours to extract the proteogly-
cans. At the end of this incubation, the media was recovered
and stored at -20°C. Unincorporated 35SO4
2- from media was
chromatographically separated using PD-10 columns (Phar-
macia, Piscataway, NJ, USA), and radiolabeled GAGs
released into the culture media or recovered from the alkaline
treatment were quantified by scintillation counting, as
described previously [39].
Histology
On day 7, the rabbits were euthanized by Beuthanasia-D
(Schering Plough Animal Health Corp., Union, NJ, USA) over-
dose, and the knee joints collected. Synovial capsules were
immersion-fixed in 10% buffered formalin for several days. The
fixed tissues were then dehydrated in a gradient of alcohols,
paraffin embedded, sectioned at 5 µm, mounted on glass
slides, and then stained using hematoxylin and eosin. Sections
were examined by light microscopy at 20× magnification.
Statistical analysis
Data were analyzed using the Microsoft Excel graphing and
statistical program. The Student's t test assuming unequal var-
iances were performed to determine significant differences
between groups. P  < 0.05 was considered statistically
significant.
Results
Expression of hIL-10, vIL-10, and mut.hIL-10 after intra-
articular injection of recombinant adenovirus into the 
rabbit knee
To compare the therapeutic effects of hIL-10, vIL-10, and
mut.hIL-10 in a rabbit knee model of antigen induced arthritis,
Figure 1
Intra-articular expression of human IL-10 (hIL-10), viral IL-10 (vIL-10),  and mutant human IL-10 (mut.hIL-10) Intra-articular expression of human IL-10 (hIL-10), viral IL-10 (vIL-10), 
and mutant human IL-10 (mut.hIL-10). Twenty-four hours post antigen-
induced arthritis (AIA) induction, 5 × 109 particles of Ad.hIL-10, Ad.vIL-
10, Ad.mut.hIL-10 or adenovirus expressing enhanced green fluores-
cent protein (Ad.eGFP; as control) were injected into knees. At days 3 
and 7 after injection of the virus, the knees were lavaged and levels of 
hIL-10, vIL-10, and mut.hIL-10 expression determined in the recovered 
lavage fluids by a cytokine ELISA kit. All values shown represent the 
mean ± standard error of the mean.
Figure 2
Effect of human IL-10 (hIL-10), viral IL-10 (vIL-10), and mutant human  IL-10 (mut.hIL-10) on leukocytic infiltration Effect of human IL-10 (hIL-10), viral IL-10 (vIL-10), and mutant human 
IL-10 (mut.hIL-10) on leukocytic infiltration. Twenty-four hours after anti-
gen-induced arthritis (AIA) initiation, rabbits received Ad.hIL-10, Ad.vIL-
10, Ad.mut.hIL-10 or adenovirus expressing enhanced green fluores-
cent protein (Ad.eGFP). On days 3 and 7 after adenovirus delivery, the 
knees were lavaged and the number of leukocytes counted in the 
recovered lavage fluid using a hemocytometer. Naïve rabbit control leu-
kocyte levels averaged about 104 cells/ml. All values are represented as 
the mean ± standard error of the mean. Asterisks denote values that 
differ at p < 0.05 (Student's t test).Arthritis Research & Therapy    Vol 8 No 4    Keravala et al.
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disease was induced by intra-articular injection of OVA into
the knees of OVA immunized rabbits. Twenty-four hours post
induction, 5 × 109 particles of first generation Ad.5-based vec-
tors encoding either hIL-10, vIL-10, mut.hIL-10 or eGFP under
the regulation of the cytomegalovirus enhancer/promoter were
injected intra-articularly into rabbit knees. A naïve control
group of rabbits was also included. Lavages were performed
using saline on days 3 and 7 after adenoviral delivery, and the
levels of hIL-10, vIL-10, and mut.hIL-10 in the recovered lav-
age fluids determined using a cytokine ELISA. ELISA meas-
urements showed similar levels of expression of hIL-10, vIL-10,
and mut.hIL-10 (Figure 1). IL-10 was not detected in sera
(data not shown) of any of the treated animals or in the lavage
fluids of knees that received Ad.eGFP.
Effect of hIL-10, vIL-10, and mut.hIL-10 expression on 
joint inflammation
Leukocytosis is one quantitative measure of inflammation. To
test and compare the ability of hIL-10, vIL-10, and mut.hIL-10
to inhibit inflammation in the inflamed rabbit knees, the number
of leukocytes in the lavage fluids at days 3 and 7 were deter-
mined. The arthritic knee joints that received Ad.eGFP exhib-
ited severe joint inflammation with a mean level of infiltrating
leukocytes exceeding 15.16 × 106 cells per ml of lavage fluid
at day 3, and exceeding 14.86 × 106 cells per ml of lavage
fluid at day 7 (Figure 2). In comparison, lavage fluid from joints
that received Ad.hIL-10 showed an average of 6.14 × 106 leu-
kocytic cells per ml, a 60% reduction on day 3 with the number
of cells reducing to 1.92 × 106 per ml, an 87% reduction by
day 7. Similarly, leukocytic infiltrates from Ad.vIL-10 and
Ad.mut.hIL-10 knees showed 51% and 55% reduction on day
3, and 72% and 93% reduction by day 7, respectively. The
control, naïve rabbit knees showed an average of 104 leuko-
cytes per ml.
Effect of hIL-10, vIL-10, and mut.hIL-10 expression on 
cartilage matrix metabolism
GAG release into the synovial fluid is used as an index to
determine cartilage matrix degradation. As shown in Figure 3a,
hIL-10, vIL-10, and mut.hIL-10 repressed proteoglycan break-
down equally. The arthritic control knees receiving Ad.eGFP
had very high levels of GAGs released into their lavage fluids
whereas, on day 3, the Ad.hIL-10, vIL-10 or mut.hIL-10 treated
knees showed a significant reduction of approximately 30%.
By day 7, this reduction had further increased to approximately
46%, a level that was similar to naïve rabbit knees.
GAG synthesis is another parameter of cartilage matrix metab-
olism. To determine and compare the ability of hIL-10, vIL-10,
and mut.hIL-10 to synthesize GAGs, 35S incorporation into
proteoglycans of articular cartilage from femoral condyles was
measured at day 7. GAG synthesis in arthritic, Ad.eGFP
treated control knees was 61% of naïve joints (Figure 3b). In
contrast, the level of GAG synthesis in knees that received
Ad.hIL-10 was 99.5%, Ad.vIL-10 was 97%, and Ad.mut.hIL-
10 was 82% that of naïve control knees.
Figure 3
Effect of human IL-10 (hIL-10), viral IL-10 (vIL-10), and mutant human IL-10 (mut.hIL-10) on cartilage matrix metabolism Effect of human IL-10 (hIL-10), viral IL-10 (vIL-10), and mutant human IL-10 (mut.hIL-10) on cartilage matrix metabolism. Twenty-four hours after anti-
gen-induced arthritis (AIA) induction, rabbit knees received either Ad.hIL-10, Ad.vIL-10, Ad.mut.hIL-10 or adenovirus expressing enhanced green flu-
orescent protein (Ad.eGFP). At days 3 and 7, the knees were lavaged, and on day 7 the animals sacrificed and their knee joints collected. (a) As a 
measure of proteoglycan breakdown, the glycosaminoglycans (GAGs) released into the lavage fluids, were measured spectrophotometrically. (b) To 
measure the rates of proteoglycan synthesis, pieces of articular cartilage from the femoral condyles were used, and their in vitro 35S04
2- incorpora-
tion into macromolecular material measured. All values are expressed as the mean ± standard error of the mean. Asterisks denote values that differ 
at p < 0.05 (Student's t test).Available online http://arthritis-research.com/content/8/4/R91
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Histological analysis
Histological analysis was done on tissues obtained from naïve
and AIA rabbit knee joints (Figure 4). Compared to the naïve
rabbit knee tissue (Figure 4a), sections from arthritic control
knees that received Ad.eGFP appeared to have acute synovi-
tis, typical of AIA (Figure 4b). The synovium was highly thick-
ened, fibrous, hypertrophic, and hyperplasic due to excessive
proliferation of synovial cells and infiltration by mononuclear
leukocytes. Tissues obtained from AIA rabbit knees treated
with Ad.hIL-10, Ad.vIL-10 or mut.hIL-10 (Figure 4c–e) were all
more or less identical to the naïve control tissue, suggesting
that Ad.hIL-10, Ad.vIL-10, and Ad.mut.hIL-10 were fairly effica-
cious in halting the progression of disease.
Discussion
IL-10 is an important multifunctional cytokine that mediates the
inflammatory response. The human homologue is immunostim-
ulatory, immunosuppressive or anti-inflammatory depending
upon the target tissue [15], whereas the viral homologue
appears to be predominantly immunosuppressive and anti-
inflammatory [27]. The biologically active mut.hIL-10 with a
substituted alanine at position 87 has only immunosuppres-
sive and anti-inflammatory capabilities similar to vIL-10 [28].
Experiments have shown that mut.hIL-10, like vIL-10, prevents
mast cell proliferation and prolongs allograft survival in mice
[28,30].
Previous studies have examined the effects of vIL-10 in the AIA
rabbit model as well as the collagen induced arthritis mouse
model showing efficacious results for treatment
[11,12,32,33]. However, the cellular form of IL-10 has not
been examined in the AIA model, and vIL-10 and mut.hIL-10
not compared in either rabbit or rodent models. In addition, it
has been speculated that since mut.hIL-10 only has immuno-
suppressive and anti-inflammatory characteristics, it might be
a superior cytokine for therapy of inflammatory diseases, as it
would be less antigenic than vIL-10.
In this report, we have examined and compared the therapeu-
tic potential of hIL-10, vIL-10, and mut.hIL10 in the AIA rabbit
model. We have demonstrated that local adenovirus-mediated
intra-articular gene transfer of hIL-10, vIL-10 or mut.hIL-10 in
Figure 4
Histological analysis of synovial tissue recovered from the rabbit knees Histological analysis of synovial tissue recovered from the rabbit knees. Twenty-four hours after antigen-induced arthritis (AIA) induction, rabbits 
received either Ad.hIL-10, Ad.vIL-10, Ad.mut.hIL-10 or Ad.eGFP. On day 7 after the adenoviral delivery, the rabbits were sacrificed, and synovial tis-
sue harvested, fixed, sectioned, and stained with hematoxylin and eosin. (a) Synovium from a naïve control rabbit knee. (b) Synovium from an AIA 
rabbit knee that received Ad.eGFP as an inflamed control. (c) Synovium from an AIA rabbit knee that was treated with Ad.hIL-10. (d) Synovium from 
an AIA rabbit knee that was treated with Ad.vIL-10. (e) Synovium from an AIA rabbit knee that was treated with Ad.mut.hIL-10. hIL-10, human IL-10; 
mut.hIL-10, mutant human IL-10; vIL-10, viral IL-10; eGFP, enhanced green fluorescent protein.Arthritis Research & Therapy    Vol 8 No 4    Keravala et al.
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the rabbit knees resulted in significant improvements in several
pathologies associated with the disease. A considerable
decrease in the number of intra-articular infiltrating leukocytes
as well as the degree of synovitis in the knee joints was
observed. In addition, these cytokines displayed not only a
chondroprotective effect in blocking cartilage matrix break-
down but also a chondrogenic effect in maintaining new carti-
lage matrix synthesis. Interestingly, our data suggest that hIL-
10 effectively blocked the progression of the disease in the
knees of the AIA rabbits despite its immunostimulatory func-
tion. Furthermore, the mutant form of hIL-10 was as effective
as vIL-10 in inhibiting the AIA in rabbits, but not more effective
than wild-type IL-10.
A previous study from our group has shown that TNF-α levels
in rabbit arthritic knees were reduced by vIL-10 treatment [11].
Additional studies have shown vIL-10 to be able to inhibit the
production of pro-inflammatory cytokines such as TNF-α and
T cell growth factors, as well as block antigen presentation on
macrophages and dendritic cells [20-24]. Thus, it is likely that
the therapeutic effects of hIL-10 and mut.hIL-10 are also due
partially to the suppression of TNF-α, or blockage of antigen
presentation on antigen-presenting cells.
The application of gene therapy represents a novel approach
for the treatment of RA, overcoming obstacles of protein deliv-
ery while providing a sustainable high efficacy and greater
safety. Multiple studies in different animal models with direct
viral gene transfer of therapeutic agents provide proof sup-
porting the use of gene therapy in arthritis [9-13,32,33], and a
recent phase I clinical trial using IL-1Ra by ex vivo gene trans-
fer to arthritic joints was also successfully completed [40,41].
Systemic non-viral delivery methods, such as administration of
engineered syngeneic fibroblasts [42], and intranasal delivery
of plasmid DNA [43] also show promise.
Although shown in several experimental animal models to be
an effective therapeutic for arthritis [11,12,32,33], vIL-10 has
not been considered for clinical gene therapy use. It is a for-
eign protein and would consequently generate a neutralizing
immune response undermining its potential as a therapeutic.
However, hIL-10 and presumably mut.hIL-10 would be recog-
nized as self and would escape the immune response. Both
these cytokines have shown significant therapeutic efficacy in
our study using the AIA rabbit model and could hence have
considerable potential for development of clinical gene ther-
apy approaches for RA.
Conclusion
In this report, we demonstrate by adenoviral-mediated intra-
articular gene transfer to the rabbit knee that hIL-10, vIL-10,
and mut.hIL-10 are all similarly effective in blocking the pro-
gression of antigen induced arthritis. In particular, the three
forms of IL-10 were all successful in reducing intra-articular
leukocytosis and the degree of synovitis, as well as normalizing
cartilage matrix metabolism. These results demonstrate that
hIL-10 and mut.hIL-10, which are non-immunogenic compared
to vIL-10, would be as efficacious as vIL-10 in treating arthritis
pathologies following intra-articular gene transfer.
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